MSB 7.69% $1.19 mesoblast limited

CLICK HERE for Breaking Story on Spanish COVID-19...

  1. 464 Posts.
    lightbulb Created with Sketch. 887
    CLICK HERE for Breaking Story on Spanish COVID-19 trial:
    https://www.dailymail.co.uk/news/article-8502987/Stem-cell-therapy-boosts-Covid-19-survival-rates-FIVE-fold-critically-ill-patients.html

    In my opinion, there is a 95% chance that these Stem Cell's were supplied by Mesoblast's licensee Takeda (Alofisel®)
    Principal Investigators are:
    * Professor Bernat Soria from the Miguel Hernández University (UMH).
    * Professor Damián García Olmo from the Fundación Jiménez Díaz.

    Initial news story about this Covid-19 trial in Spain:
    https://www.elplural.com/sociedad/hospitales-universidades-espanolas-investigan-farmaco-pacientes-graves-coronavirus_236193102

    Professor Damián García Olmo's tweet about Mesoblast's licensee Takeda (Alofisel®):
    https://twitter.com/garciaolmod/status/977559554580975617

    Mesoblast's partnership with Takeda (Alofisel®):
    https://www.mesoblast.com/partnerships/overview

    More references of Professor Damián García Olmo's work with Mesoblast's licensee Takeda (Alofisel®)
    https://elmedicointeractivo.com/takeda-firma-con-el-ministerio-un-acuerdo-de-riesgo-compartido-para-financiar-alofisel/
    https://gacetamedica.com/investigacion/la-primera-terapia-celular-alogenica-ya-esta-disponible-en-espana-hi2280180/





 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.